(42) showed carboplatin activated the STING/TBK1/IRF3 signaling pathway and the STING-NF-κB signaling pathway, then experimentally verified that low dose of carboplatin could increase PD-L1 expression in lung cancer cells. Here, STING1 is linked to lung cancer.